Addresses
This report describes a 37-year-old female patient who after seven years on intermittent overnight enteral feeding supplementation was noted to have an increased whole blood manganese concentration. Manganese toxicity is well documented after pathological absorption through inhalation via the lungs, or after intravenous administration to patients on long-term total parenteral nutrition. A dietary history revealed high tea consumption. The association between high blood manganese concentrations and enteral/oral nutrition does not appear to have previously been described. 
Case report
A 33-year-old woman was admitted to Glasgow Royal In¢rmary in 1996 with acute onset abdominal pain and abnormal liver function tests. A diagnosis of gastric necrosis secondary to coeliac axis thrombosis was made. Further investigation con¢rmed that she had an underlying coagulopathy, FactorV Leiden heterozygote status. She underwent urgent total gastrectomy and Roux-en-Y surgical reconstruction plus an aortohepatic graft for hepatic revascularization. At initial presentation, her liver function tests were deranged with an aspartate aminotransferase (AST) of 260 IU/L (reference interval o38 IU/L), and an alanine aminotransferase (ALT) of 225 IU/L (reference interval o41 IU/L). Postoperatively, these returned to within the reference range and subsequently remained normal. At surgery, 50 cm of small bowel was removed; histology did not show any evidence of in£ammatory bowel disease.
She had been admitted in April 1995 with abdominal pain and a perforated peptic ulcer. Prior to 1995, she had intermittent episodes of abdominal pain and vomiting with no underlying cause identi¢ed. She was noted to be persistently underweight (Body Mass Index [BMI] of between 15 and 16.6 kg/m 2 ). After her admission in 1996, she was referred to the nutrition clinic, and overnight enteral feeding was required to maintain her weight around 40 kg (BMI 16.6 kg/m 2 ). Her enteral feed regime varied at 1 L of feed, 4--7 nights per week. Between 1996 and August 2000, she was maintained on the preparation Osmolite (Abbott Nutrition UK) and subsequently Ensure Plus (Abbott Nutrition UK).
In April 2003, she was found to have a raised whole blood manganese of 606 nmol/L (reference interval 70--280 nmol/L). This was con¢rmed on a further measurement in October 2003 with a result of 536 nmol/L. On examination, there was no clinical evidence of a Parkinson's-like syndrome or other neurological abnormalities, and a brain magnetic resonance imaging (MRI) scan was reported as normal. Her medications included warfarin, ferrous sulphate, calcium carbonate, vitamin B12 injections, folate, zinc sulphate and oral vitamin B and C supplements. She was not on any manganese-containing supplements. The enteral feed preparations contain an average of 2.5--5 mg manganese per litre, which is within the average UK dietary intake of 8.2 mg per day and below the estimated upper limit of 12.2 mg per day. 1 At a further clinic visit, a dietary history was taken. This revealed that the patient consumed a large amount of tea. The exact amount was di⁄cult to clarify but was as much as a mug of tea (approximately 150 mL) every 1--2 h during the day. Her diet was otherwise normal in content. This measure of tea contains approximately 0.39 mg manganese. 2 An estimated intake of between 6 and 12 cups per day would result in a manganese intake, from this source, of between 2.4 and 4.7 mg per day. This in fact constituted the majority of her daily £uids, and advice was given regarding reducing this intake. If this were combined with the average daily intake from food (8.2 mg) and maximum enteral feed manganese content (5 mg), then there would be a potential intake of 18 mg per day, although the average UK intake takes into account some beverage consumption, so it is di⁄cult to make accurate calculations.
On clinical follow-up, she was not exhibiting any signs or symptoms that might suggest clinical manganese toxicity. Her whole blood manganese concentrations remain increased at 618 nmol/L in January 2005 and 605 nmol/L in June 2005, but she admitted to making little reduction in her tea intake.
Discussion
Manganese is classed as an essential micronutrient, but its biological functions in man remain uncertain. It is a co-factor in enzymes such as hexokinase, superoxide dismutase and xanthine oxidase. 3 Animal studies have shown manganese de¢ciency can result in lipid abnormalities and anaemia. There has been only one documented case of human manganese de¢ciency, and this was complicated by a possible lack of vitamin K. 4 This limited evidence accounts for manganese being included in enteral and parenteral nutrition preparations.
In general, the major clinical problem encountered with manganese is toxicity. Manganese is used extensively in the iron, steel and battery production industries and is obtained through manganese ore mining. Manganese toxicity after pathological absorption through inhalation via the lungs has been well documented in manganese ore miners. 5 Manganism describes the Parkinsonian syndrome and psychiatric symptoms that develop. Excess manganese is deposited in the basal ganglia and results in the development of a Parkinsonian syndrome. This accumulation can be seen as hyper-intense areas on brain MRI imaging.
Manganese toxicity has recently been documented in long-term parenteral nutrition patients. 6, 7 The main regulatory factor in manganese homeostasis is thought to be via absorption in the gut. Parenteral administration bypasses this step and there has been uncertainty about the appropriate intravenous dose. Initial reports of toxicity were in patients receiving 2.2 mg of manganese per day, but there have been subsequent reports of patients supplemented with 0.28 mg per day showing evidence of toxicity. 6, 8 Manganese is primarily excreted in the bile, and parenteral nutrition patients with liver dysfunction are particularly at risk of manganese toxicity. 6 The main source of manganese is the diet. Rich sources include grains, nuts, eggs, tea and co¡ee. 3 There have been epidemiological reports of manganese toxicity secondary to consumption of contaminated drinking water, but they lack both qualitative and quantitative data to enable a de¢nite link to be made. 1 Ingestion of excess manganese is presumed to result in decreased absorption, although the mechanism for this is not known. There have been no reported cases of manganese toxicity in patients on enteral nutrition. A literature search revealed one documented case of oral manganese toxicity in a female patient with hereditary haemorrhagic telangiectasia and porto-systemic shunting, where the excretion mechanisms for manganese were presumed to be impaired. 9 This report stated that the patient consumed a normal diet, and that at presentation had some derangement of liver function tests and iron de¢ciency anaemia. Finley demonstrated that women absorb a greater percentage of manganese than men, and manganese absorption is further enhanced in women with low iron stores. 10 The patient in this case report was maintained on an oral iron preparation and her iron indices were within the relevant reference ranges.
The patient we describe consumed large quantities of tea, which is a rich source of manganese. Analysis for other trace metals that may be found in signi¢cant quantities in tea, such as £uoride or aluminium, was not performed. Impairment of liver function or porto-systemic shunting interferes with manganese handling and may predispose to increased levels. In addition, there may be a link between the genetic condition itself and excess manganese absorption. Other genetic conditions, such as haemochromatosis, that may a¡ect trace element uptake in the gut were not speci¢cally looked for. This patient had normal liver function tests and a functioning aorto-hepatic stent, but subtle alterations in liver function may be enough to a¡ect the homeostatic mechanisms for manganese.
